Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes    » A1c    » Adolescents    » Awareness    » Cause    » Children    » Complications    » Control    » Costs    » Cure    » Diagnosis    » Drugs    » Elderly    » Gestational    » Hypoglycemia    » Impaired Fasting Glucose    » Impaired Glucose Tolerance    » Inflammation    » Insulin Resistance    » Insulin Sensitivity    » Men    » Metabolic Syndrome    » Minorities    » Obesity    » Organs    » Other Diseases    » Pancreas    » Pre-Diabetes    » Prevention    » Research    » Risk Factors    » Screening    » Statistics    » Stress    » Syndrome X    » Testing    » Treatments    » Type 1    » Type 2    » Warning Signs    » Women Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

About Diabetes » Treatments

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

EASD: New Drug Classes Entering Type 2 Pipeline Posted: Sunday, October 03, 2010

Farnesoid X receptor agonists, 11-â-HSD1 inhibitors, and glucokinase activators are some of the new approaches to treating Type 2 diabetes described in research presented, but some senior researchers expressed doubts about the clinical need for them.

EASD: Once-Weekly Exenatide Benefit Sustained over 52 Weeks Posted: Sunday, October 03, 2010

Once-Weekly Exenatide maintains a drop in A1c of 2 points for more than 52 weeks.

EASD: Moderate Wine Drinking Lowers Fasting Glucose in Type 2 Diabetes Posted: Sunday, October 03, 2010

A glass of merlot or perhaps sauvignon blanc with dinner may offer modest benefits for patients with Type 2 diabetes, said researchers.

EASD: Weight Loss with SGLT2 Inhibitors but More Infections Posted: Sunday, October 03, 2010

Three possible first in class drugs in the sodium glucose co-transporter (SGLT2 inhibitor) class showed improvements in glycemic control and weight loss, but infections proved troublesome, researchers reported.

EASD: Adding Incretin to Insulin Lowers HbA1c Posted: Sunday, October 03, 2010

Adding exenatide to insulin glargine for patients who aren't fully controlled with insulin glargine and/or other oral agents can help to improve their blood glucose.

Gel Technology Utilized in New Artificial Pancreas Posted: Wednesday, September 29, 2010

A researcher has developed an artificial pancreas that she says could revolutionize the treatment of diabetes.

Transdermal GLP-1 Patch for Type 2 Diabetes Posted: Wednesday, September 29, 2010

TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes.

New First in Class Type 2 Diabetes Drug Cycloset® Launches November Posted: Tuesday, September 21, 2010

VeroScience announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize Cycloset®, which has been approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes both as mono-therapy and in combination with other oral antidiabetic agents.

Significant Type 2 Diabetes Breakthrough Posted: Tuesday, September 21, 2010

Amyloid could "directly poison" pancreas cells. Shedding light on how a malfunctioning protein helps trigger Type 2 diabetes could one day offer the chance to halt the damage, say scientists.

AADE Stresses the Treatment of Obesity as a Means of Preventing Diabetes Posted: Tuesday, September 21, 2010

The American Association of Diabetes Educators has issued a formal position statement and set of recommendations urging diabetes educators to proactively address obesity as a means of preventing the onset of Type 2 diabetes, managing complications for those who already have the disease, and creating a savings for the overall health care system.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.